Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
Richard G EversonYuuri HashimotoJacob L FreemanTiffany R HodgesJason HuseShouhao ZhouJoanne XiuDavid SpetzlerNader SanaiLyndon KimSantosh KesariAndrew BrennerFranco De MonteAmy B HeimbergerShaan M RazaPublished in: Journal of neuro-oncology (2018)
If predicated on tumor expression, our data suggest that therapeutics directed toward NF2 and TOP2A could be considered for most meningioma patients.